A major medical marijuana company is under fire from the FDA. The agency sent Curaleaf a letter of warning over concerns that the cannabis company is







FDA warns Curaleaf about inflated claims in CBD product marketing [XtMRUgFrBu2]

FDA warns Curaleaf about inflated claims in CBD product marketing [XtMRUgFrBu2]

| 1h 28m 28s | Video has closed captioning.

A major medical marijuana company is under fire from the FDA. The agency sent Curaleaf a letter of warning over concerns that the cannabis company is marketing some of its products containing CBD as being effective treatments for cancer, Alzheimer's disease, opioid withdrawal and pain.

Aired: December 12, 2024

Rating: TV-14

Buy Now:

Problems Playing Video? | Closed Captioning

Related to This Episode

  • Q&A with Heidi Thomas

    Q&A with Heidi Thomas

    Writer & Executive Producer of FDA warns Curaleaf about inflated claims in CBD product marketing [XtMRUgFrBu2] on the secret of the show.

  • Relive the Drama with Gif Recaps

    Relive the Drama with Gif Recaps

    Miss an episode? Catch up on all things Poplar with our gif recaps.

  • Visit the Official Site

    Visit the Official Site

    Dive deeper into FDA warns Curaleaf about inflated claims in CBD product marketing [XtMRUgFrBu2] with cast Q&As, expert blogs, BTS photos, and more!

  • Explore the Modern Midwives Blog

    Explore the Modern Midwives Blog

    Experienced midwives discuss how FDA warns Curaleaf about inflated claims in CBD product marketing [XtMRUgFrBu2] intersects with modern day Midwifery.

Learn About Midwifery Today

Blog

Learn About Midwifery Today

Read the Modern Day Midwives Blog and learn more about our bloggers, all experienced midwives.

Read now